The Quantellect read.As of Nov 19, 2026, 5 active firms cover Apyx Medical Inc: 5 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets are tightly clustered, $6.00 to $7.00, so the covering firms are broadly aligned. The average target of $6.20 sits 149% above the current $2.49. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees revenue growth near 13% this year and 10% next, consensus EPS building from about $-0.06 next quarter toward $-0.19 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS5 active firms
Buy
Strong Buy00%
Buy5100%
Neutral00%
Sell00%
Strong Sell00%
Based on 5 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$6.20
+149.0% upside
Average target across 5 active firms as of Nov 19, 2026 vs $2.49 current
Highest Target$7.00
Average Target$6.20
Lowest Target$6.00
Detailed analyst forecasts for APYX
Showing 1–4 of 4 named analysts shown · 5 active firms in the rating projection
As of Nov 19, 2026, 5 of 5 active firms rate APYX a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
APYX EPS & revenue forecast
EPS · NEXT QUARTER
$-0.06
Range $-0.09 – $-0.04 · 5 analysts · +28% YoY
Next period, 5 analysts expect Apyx Medical Inc to earn $-0.06 a share (range $-0.09 – $-0.04), versus $-0.05 a year earlier. Full-year consensus is $-0.20, growing to $-0.19 the year after.
REVENUE · NEXT QUARTER
$13.6M
Range $13.2M – $13.9M · 5 analysts · +6% YoY
Revenue is expected to reach $13.6M (range $13.2M – $13.9M), +6.0% year-over-year. Full-year consensus is $59.6M, rising to $65.8M next year.
Top analysts covering Apyx Medical Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on APYX.
#1
Yi Chen
HC Wainwright & Co. · Rank #350
Buy
$7.00+181.1% to target
Overall win rate
34%
+ Follow
#2
David Turkaly
JMP Securities · Rank #453
Buy
$8.00+221.3% to target
Overall win rate
35%
+ Follow
#3
KB
Kyle Bauser
Roth Capital
Buy
$6.00+141.0% to target
Coverage
—
+ Follow
#4
MH
Matthew Hewitt
Craig-Hallum
Buy
$6.00+141.0% to target
Coverage
—
+ Follow
#5
SE
Sam Eiber
BTIG
Buy
$6.00+141.0% to target
Coverage
—
+ Follow
APYX stock forecast FAQ
What is APYX's average 12-month price target?+
The 5 active firms with a live target average $6.20 for Apyx Medical Inc over the next 12 months, ranging from a $7.00 high to a $6.00 low, as of Nov 19, 2026.
Is APYX stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 5 active firms as of Nov 19, 2026, 5 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for APYX?+
The Street-high target is $7.00 (HC Wainwright & Co.), and the Street-low is $6.00 (Craig-Hallum). The average of all 5 active-firm targets is $6.20.
How many active Wall Street firms cover APYX?+
5 active firms have a recognized rating on Apyx Medical Inc as of Nov 19, 2026, and 5 active firms carry a live 12-month price target.
Who is the most accurate analyst covering APYX?+
Among analysts who currently cover APYX, Yi Chen of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #350). Their current call is Buy with a $7.00 target.
What is Apyx Medical Inc's projected EPS for next quarter?+
The consensus estimate is $-0.06 per share (range $-0.09 – $-0.04) across 5 analysts. Full-year EPS is projected at $-0.20, rising to $-0.19 the following year.
How much revenue is Apyx Medical Inc expected to report next quarter?+
Consensus revenue is $13.6M (range $13.2M – $13.9M). Full-year revenue is projected at $59.6M, growing to $65.8M next year.
Have analysts been upgrading or downgrading APYX lately?+
As of Nov 19, 2026, 5 of 5 active firms rate APYX a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their APYX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.